Title: Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Version: 1 Date: 15 Apr 2023
Reviewer's report:
Chen et al have demonstrated that serum liver fibrosis markers, particularly in collagen IV,
predicted liver decompensation in patients with compensated cirrhosis.
The comments are listed below:
1. In the section of “follow-up and study outcomes” (Page 5, Line 4), the authors defined variceal
bleeding as portal hypertension related bleeding requiring hospital admission. However, portal
hypertension related bleeding included variceal bleeding or bleeding from portal hypertensive
gastropathy. The definition should be addressed clear.
2. Regarding etiologies of cirrhosis, HBV and HCV accounts for 70.6% and 13.8%, respectively.
Did those patients receive anti-viral agents?
3. The authors analyze the predictive values of liver fibrosis markers, and LN and CIV
independently predict hepatic decompensation. There are some noninvasive indexes could
represent the severity of liver fibrosis including FIB-4 and APRI. Are those markers superior to
FIB-4 or APRI in prediction of hepatic decompensation?
Title: Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Version: 1 Date: 15 Apr 2023
Reviewer's report:
Chen et al have demonstrated that serum liver fibrosis markers, particularly in collagen IV,
predicted liver decompensation in patients with compensated cirrhosis.
The comments are listed below:
1. In the section of “follow-up and study outcomes” (Page 5, Line 4), the authors defined variceal
bleeding as portal hypertension related bleeding requiring hospital admission. However, portal
hypertension related bleeding included variceal bleeding or bleeding from portal hypertensive
gastropathy. The definition should be addressed clear.
2. Regarding etiologies of cirrhosis, HBV and HCV accounts for 70.6% and 13.8%, respectively.
Did those patients receive anti-viral agents?
3. The authors analyze the predictive values of liver fibrosis markers, and LN and CIV
independently predict hepatic decompensation. There are some noninvasive indexes could
represent the severity of liver fibrosis including FIB-4 and APRI. Are those markers superior to
FIB-4 or APRI in prediction of hepatic decompensation?
Please review this paper.
user
Title: Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
Version: 1 Date: 15 Apr 2023
Reviewer's report:
Chen et al have demonstrated that serum liver fibrosis markers, particularly in collagen IV,
predicted liver decompensation in patients with compensated cirrhosis.
The comments are listed below:
1. In the section of “follow-up and study outcomes” (Page 5, Line 4), the authors defined variceal
bleeding as portal hypertension related bleeding requiring hospital admission. However, portal
hypertension related bleeding included variceal bleeding or bleeding from portal hypertensive
gastropathy. The definition should be addressed clear.
2. Regarding etiologies of cirrhosis, HBV and HCV accounts for 70.6% and 13.8%, respectively.
Did those patients receive anti-viral agents?
3. The authors analyze the predictive values of liver fibrosis markers, and LN and CIV
independently predict hepatic decompensation. There are some noninvasive indexes could
represent the severity of liver fibrosis including FIB-4 and APRI. Are those markers superior to
FIB-4 or APRI in prediction of hepatic decompensation?
assistant